HC Wainwright & Co. Reiterates Buy on NovoCure, Lowers Price Target to $46

Benzinga Newsdesk www.benzinga.com Negative 84.4%

Neg 84.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and lowers the price target from $48 to $46.